Diagnostic gene expression profile (GEP) for improving precision and molecular classification of hematological malignancies

4^th World Congress on Cancer Science & Therapy

October 20-22, 2014 DoubleTree by Hilton Hotel Chicago-North Shore Conference Center, USA

Yossi Cohen, Odit Gutwein, Osant Garach-Jehoshua, Adina Bar-Haim and Abraham Kornberg

Accepted Abstracts: J Cancer Sci Ther

Abstract :

GEP is a powerful tool for investigation and risk group stratification. Recently we have started looking at the utility of GEP in the diagnosis setup. Our preliminary results show significant contribution of GEP to correct diagnosis and management of hematological malignancies, especially when immunophenotype is not unequivocal. Moreover, in certain cases GEP added to a more accurate lineage specification, for example by identifying high TdT expression, which was missed at the protein level. In other cases aberrant expression of various signaling molecules was evident, which opens the door for personalizing the treatment. On the basis of these findings, we intend to start classifying each of the common hematological malignancies and the various clinico-pathological entities using GEP as the main molecular classifier, taking the advantage of its whole genome coverage, the observer independence and the ability to personalize the treatment on the basis of expressed pathways and signatures.

Biography :

Yossi Cohen, MD, BSc, is specialized in hematology and was training on Molecular Cell Biology laboratory in the Weizmann Institute of Science, Israel. In the previous years he published several papers on the regulation of primary bone marrow tumor cells by the niche and a chapter in a book (Nova Publication, 2014) on the mechanism of action of novel antimyeloma agents.